Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen–progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women

Tilly-Kiesi, Marju; Kahri, Juhani; Pyörälä, Tapani; Puolakka, Jukka; Luotola, H.; Lappi, Mikko; Lahdenperä, Sanni; Taskinen, Marja‐Riitta

doi:10.1016/s0021-9150(96)06036-4

Cited by 21 publications

(11 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were reported by a Finnish group [38]. They demonstrated a clear TG enrichment of all HDL subclasses after oral estrogens and no such effect when estrogens were administered transdermally.…”

Section: Discussionsupporting

confidence: 88%

Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins

et al. 2008

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins

et al. 2008

View full text Add to dashboard Cite

“…Serum apoA1 and apoA2 concentrations were measured by an immunoturbidimetric method with commercially available kits (Boehringer Mannheim, Mannheim, Germany) (31). The concentration of LpA1 particles was quantified using a differential electroimmunoassay with hydrated agarose gels containing monospecific antibodies against apoA1 and apoA2 (Sebia, France) as previously described (31).…”

Section: Measurement Of Lipids and Lipoproteinsmentioning

confidence: 99%

“…The concentration of LpA1 particles was quantified using a differential electroimmunoassay with hydrated agarose gels containing monospecific antibodies against apoA1 and apoA2 (Sebia, France) as previously described (31). This method directly quantifies the LpA1 particles as the concentration of apoA1 in these particles.…”

Section: Measurement Of Lipids and Lipoproteinsmentioning

confidence: 99%

Differing Associations of Lipid and Lipoprotein Disturbances With the Macrovascular and Microvascular Complications of Type 1 Diabetes

Chaturvedi

Fuller²,

Taskinen³

2001

Diabetes Care

Self Cite

View full text Add to dashboard Cite

OBJECTIVE -Cardiovascular disease (CVD) is increased in patients with type 1 diabetes, but lipid and lipoprotein patterns remain favorable. In contrast, nephropathy is associated with an adverse distribution. We compared the associations and predictive power of lipid and lipoprotein disturbances with these complications. RESEARCH DESIGN AND METHODS-A nested case-control study from the EURODIAB cohort of 140 case subjects with evidence of at least one complication and 84 control subjects with no complications were analyzed. Conventional and unconventional lipid and lipoprotein fractions, including apolipoprotein (apo)-A1, lipoprotein (Lp)-A1, LpA1/A2, apoB, and LDL particle size were measured centrally.RESULTS -CVD was only associated with increased LDL cholesterol (3.6 vs. 3.0 mmol/l, P ϭ 0.02). In contrast, albuminuria was associated with elevated cholesterol, triglyceride, LDL, and apoB and with diminished LDL particle size. No disturbances in HDL and related lipoproteins were noted. In normoalbuminuric patients, CVD was not associated with any significant changes in lipids. CVD in macroalbuminuric patients was associated with increased triglyceride level (2.37 vs. 1.07 mmol/l, P ϭ 0.001; P ϭ 0.02 for CVD/albuminuria interaction) and LDL cholesterol (5.4 vs. 3.3 mmol/l, P ϭ 0.005; P ϭ 0.004 for interaction). Independent associations were observed for total cholesterol and for LDL particle size and albuminuria.CONCLUSIONS -Abnormalities in lipid and lipoprotein disturbances are more closely related to albuminuria than to CVD in patients with type 1 diabetes. Measurement of conventional parameters provide sufficient risk information. ApoB and LDL particle size offer limited extra information. HDL metabolism remains undisturbed in the presence of complications. These changes reflect associations with glycemic control, which is the key to understanding lipid and lipoprotein disturbances.

show abstract

“…Estrogen deficiency per se does not alter plasma CETP activity as shown in castrated CETP transgenic mice (15). Also, estrogen therapy has no impact on the plasma CETP activity in humans (16) as well as in apolipoprotein B/CETP double transgenic mouse model (17).…”

mentioning

confidence: 93%

Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice

Cazita

Berti

Aoki

et al. 2003

Journal of Lipid Research

View full text Add to dashboard Cite

(2); however, the precise effects of CETP on atherogenesis are controversial. In humans, increased incidence of coronary heart disease has been associated with both CETP deficiency (3) and augmentation (4). In several animal models of atherosclerosis, the effects of CETP on vascular health are clearly dependent upon the metabolic context (5-11).Various researchers are attempting to target CETP as a form of therapy (9-13), but these approaches will be useless unless the circumstances where CETP acts as pro-or anti-atherogenic are properly clarified.Deficiency in endogenous estrogen accounts for the loss of protection against coronary heart disease after menopause or following bilateral ovariectomy (14). Estrogen deficiency per se does not alter plasma CETP activity as shown in castrated CETP transgenic mice (15). Also, estrogen therapy has no impact on the plasma CETP activity in humans (16) as well as in apolipoprotein B/CETP double transgenic mouse model (17).The present study aimed at investigating whether CETP expression would alter the development of atherosclerosis in a moderately hypercholesterolemic mouse model lacking ovarian hormones. For this purpose, mice expressing the human CETP gene were crossbred with LDL receptor (LDLR) knockout mice. On a high fat diet, the LDLR knockout mice develop extensive aorta atherosclerosis in a pattern similar to humans (18,19). We have shown here that the expression of the CETP gene significantly reduced the development of atherosclerotic lesions in ovariectomized hypercholesterolemic mice. Furthermore, this antiatherogenic effect of CETP was blunted by the estrogen replacement therapy.

show abstract

Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen–progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women

Cited by 21 publications

References 66 publications

Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins

Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins

Differing Associations of Lipid and Lipoprotein Disturbances With the Macrovascular and Microvascular Complications of Type 1 Diabetes

Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice

Contact Info

Product

Resources

About